论文部分内容阅读
目的：观察吡啦西坦片联合丁苯酞软胶囊治疗腔隙性脑梗死（LI）合并血管性认知功能障碍（VCI）的临床疗效及安全性。方法：87例 LI 合并 VCI 患者随机分为对照组（44例）和观察组（43例）。对照组单用吡拉西坦片（1．2 g tid），观察组联用吡拉西坦片（1．2 g tid）和丁苯酞软胶囊（0．2 g qid），疗程均为30 d。观察两组患者 MMSE 积分、SOD 含量变化，比较两组疗效和药品不良反应。结果：两组患者治疗后 MMSE 积分、血清 SOD 水平均较前升高（P ＜0．01），且观察组优于对照组（P ＜0．05和 P ＜0．01）。观察组总有效率86．05％，高于对照组的75．00％（P ＜0．05）。结论：吡拉西坦联用丁苯酞可有效改善 LI 合并 VCI 的认知功能损害，可能是通过提高 SOD 水平实现的。“,”Objective:To observe the clinical efficacy and safety of piracetam tablets combined with butylphthalide soft capsules in the treatment of patients with lacunar infarction(LI) complicated with vascular cognitive impairment(VCI). Methods:Totally 87 cases of patients with LI and VCI were selected and randomly divided into the control group(44 cases)and the treatment group(43 cases). The control group was only treated with piracetam tablets(1. 2 g,tid),while the treatment group was treated with piracetam tablets(1. 2 g,tid)and butylphthalide soft capsules(0. 2 g,qid),and the treatment course was 30 days. The changes of MMSE score,serum of SOD level and adverse drug reactions were observed and compared in the two groups. Results:Compared with those before the treatment,the mini-mental state examination(MMSE)score and serum level of SOD of the two groups were increased(P < 0. 01)after the treatment,and the increase in the treatment group was more notable than that in the control group(P < 0. 01and P < 0. 05). The effective rate of the treatment group was 86. 05% ,which was higher than that of the control group(75. 00% ,P < 0. 05). Conclusion:Piracetam combined with butylphthalide soft capsules can effectively improve the cognitive impairment of the patients with LI and VCI,and the effect may be related with increasing the level of SOD.